Crystalys Therapeutics
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
$130MSeries B
Role not disclosedSO
SR One
Activity from announced rounds
Activity in this selectionUnited States · Oct 23, 2026 · Jan 1, 2026
- Rounds participated in
- 4
- Confirmed lead rounds
- — 4 roles undisclosed
- New companies
- 3 First participation on record · 1 follow-on
- Funding in participating rounds
- $425M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionPoplar Therapeutics
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
$45MSeries A+
Role not disclosedAirNexis Therapeutics
AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01.
$200MSeries A
Role not disclosedPoplar Therapeutics
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
$50MSeries A
Role not disclosed